Completed PHASE2 INTERVENTIONAL NCT00200538

Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients

Sponsor: Nantes University Hospital

Conditions Dementia

Interventions memantine

Updated 5 times since 2017 Last updated: May 2, 2013 Started: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Dementia and is currently completed. Nantes University Hospital leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nantes University Hospital

Data source: Nantes University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nantes, France